Retailer & Marketplace · vs · B2C Consumer App / Platform
CVS Health vs Hims & Hers
Structured technology and market comparison · 2026
Direct Feature Comparison
CVS Health · vs · Hims & HersIntegrated US pharmacy, insurance, care delivery and retail media company.
Consumer telehealth platform with subscription-based treatment and fulfilment.
Analyze all overlapping signals and tech stacks for CVS Health and Hims & Hers
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between CVS Health and Hims & Hers?
When comparing CVS Health and Hims & Hers, both platforms operate within the Retailer & Marketplace and B2C Consumer App / Platform ecosystem. CVS Health is positioned as Integrated US pharmacy, insurance, care delivery and retail media company, whereas Hims & Hers focuses on Consumer telehealth platform with subscription-based treatment and fulfilment. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to CVS Health and Hims & Hers?
When evaluating CVS Health and Hims & Hers, enterprise buyers also consider other platforms in Retailer & Marketplace and B2C Consumer App / Platform. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of CVS Health and Hims & Hers compare?
CVS Health is headquartered in US (founding year unrecorded) with >5,000 employees. Hims & Hers is based in US (founded in 2017) with 1,001–5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: CVS Health vs Hims & Hers
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
CVS Health
Recent Signals
- ·CNBC InvestingFinancials
Goldman recommends defensive stocks amid AI bull concerns
Goldman Sachs advises investors concerned about a potential slowdown in the AI trade to consider defensive stocks in health care and consumer staples. The bank notes that AI capital spending currently contributes about half of S&P 500 earnings growth, but expects this to diminish as spending growth slows. Rising energy prices and interest rates are clouding the economic outlook, with higher financing costs raising doubts about the durability of the AI infrastructure buildout. Goldman's screen highlights companies with high free cash flow yields and recent underperformance, such as Tyson Foods (11% FCF yield, down 17% over six months) and CVS Health (9% FCF yield, down 15% in three months). Despite these defensive recommendations, Goldman's base case still expects continued earnings growth, with a potential catch-up trade in consumer-facing stocks fueled by weaker energy prices and falling interest rates anticipated in 2027.
- Goldman Sachs recommends defensive stocks in health care and consumer staples amid AI trade concerns.
- AI capital spending contributes about half of S&P 500 earnings growth, but Goldman expects this to diminish.
- Rising energy prices and interest rates are clouding the economic outlook.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for CVS Health (2026-08-05)
CVS Health Corporation reported strong financial results for the second quarter of 2026, driven by top-line growth across all major operating segments. Total revenues increased 7.3% year-over-year to $106.10 billion, up from $98.92 billion in Q2 2025. Operating income saw a substantial 97.5% increase to $4.70 billion, compared to $2.38 billion in the prior-year period, primarily supported by core operational improvements and the absence of $833 million in legacy litigation charges incurred in Q2 2025. Net income attributable to CVS Health rose significantly to $2.98 billion ($2.31 diluted EPS) from $1.02 billion ($0.80 diluted EPS). Performance in the Health Care Benefits segment reflected improved medical loss dynamics, with the Medical Benefit Ratio (MBR) declining to 87.4% from 89.9% in Q2 2025, driven by improved underlying Government business performance and the absence of prior-year premium deficiency reserves. Growth was supported by the Health Services segment, where revenues climbed 11.5% to $51.80 billion, and Pharmacy & Consumer Wellness, which posted a 2.9% increase in pharmacy same-store sales aided by Rite Aid file acquisitions. In regulatory matters, CVS reached a proposed settlement with the FTC to resolve outstanding PBM and pharmacy inquiries.
- Q2 2026 consolidated total revenues reached $106.10 billion, an increase of 7.3% year-over-year, with operating income increasing 97.5% to $4.70 billion.
- Health Care Benefits Medical Benefit Ratio (MBR) improved by 250 bps year-over-year to 87.4%, while total medical membership stood at 26.02 million as of June 30, 2026.
- Operating cash flow for the first six months of 2026 increased 64.2% year-over-year to $10.59 billion, supporting $3.29 billion in long-term debt repayments.
- ·Pixability
Pixability Appoints Norm de Greve, Former General Motors CMO and Chairman of the MMA, to its Advisory Board
Norm de Greve, former CMO of General Motors and CVS Health and Chairman of the MMA, has joined the advisory board of Pixability, a leading AI-driven technology company that helps brands maximize YouTube advertising. In an interview with AdExchanger, de Greve highlights common mistakes brands make with YouTube marketing, emphasizing the need for an integrated strategy across paid, owned, and creator channels, which most brands lack. He also notes YouTube's growing importance as a top source for AI search and advocates for a holistic approach to content and creator management. De Greve critiques current AI use in marketing, urging brands to redesign workflows around AI rather than optimize old processes. Pixability's AI-driven approach aims to help marketers analyze organic content, amplify successful strategies, and allocate budgets more effectively across YouTube's ecosystem.
- Norm de Greve, former CMO of General Motors and CVS Health and Chairman of the MMA, joined Pixability's advisory board.
- Pixability is a YouTube-focused AI company that helps brands maximize paid and owned media and leverage creators.
- De Greve advises brands to integrate paid, owned, and creator YouTube strategies.
Hims & Hers
Recent Signals
- ·PR Newswire: Advertising & MarketingPrivacy
Hims & Hers Securities Class Action Deadline Nov 2, 2026
Robbins Geller Rudman & Dowd LLP announces a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged violations of the Securities Exchange Act. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead plaintiff appointment. The lawsuit follows an FTC complaint alleging Hims & Hers shared sensitive health information with third-party advertising platforms like Meta and Snap, and misled consumers about billing. The stock dropped nearly 15% upon the FTC news. Lead plaintiff process outlined under the Private Securities Litigation Reform Act.
- FTC filed a lawsuit against Hims & Hers on July 29, 2026, alleging sharing of sensitive health data with advertising platforms.
- Hims & Hers stock declined nearly 15% following the FTC announcement.
- Robbins Geller Rudman & Dowd LLP filed a class action lawsuit (Velanki v. Hims & Hers Health, Inc.) in the Northern District of California.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for Hims & Hers (2026-08-10)
Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year-over-year, and six-month revenue of $1.36 billion (+20% YoY), driven by strong expansion in the Hers brand and international growth from acquisitions including Eucalyptus. However, the company experienced a GAAP net loss of $86.3 million for Q2 2026 (compared to net income of $42.5 million in Q2 2025), primarily impacted by a strategic transition in its U.S. GLP-1 weight loss business, non-recurring restructuring charges, increased fulfillment costs from shorter shipping cadences, and a $60 million FTC legal contingency accrual.
- Q2 2026 total revenue reached $753.21 million (+38% YoY) with ending subscribers expanding 19% YoY to 2.89 million.
- GAAP net loss was $86.29 million for Q2 2026, down from net income of $42.51 million in Q2 2025, while Adjusted EBITDA stood at $60.32 million.
- Recorded a $60.0 million legal contingency accrual related to an FTC and multi-state consumer protection lawsuit regarding subscription and cancellation practices.
- ·PR Newswire: Technology NewsPrivacy
Hims & Hers Securities Fraud Class Action Filed
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company disclosed sensitive health information to third-party advertising platforms, including Snap and Meta (Facebook), without proper consent, and misled consumers about billing practices. The FTC filed a related lawsuit on July 29, 2026, causing the stock to drop 14.73% to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
- FTC sued Hims & Hers for sharing sensitive health data with advertising platforms (Snap, Meta) and deceptive billing practices.
- Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
- Class action lawsuit filed; lead plaintiff deadline is November 2, 2026.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners CVS Health and Hims & Hers share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks